Overview
Equip your research workflow with Retatrutide (10 mg) from DEXPEP — the Canadian-owned supplier of research-grade peptides. Retatrutide (LY3437943) is a novel single-peptide triple-agonist that simultaneously targets three metabolic receptor pathways: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors.
Studied across biochemical, metabolic, and cellular research pipelines for its reproducibility, lyophilised stability, and ease of reconstitution, Retatrutide represents a significant advancement in multi-receptor experimental models. Each Retatrutide vial is sealed under nitrogen for long-term stability and individually batch-tested for identity, purity, and consistency via independent HPLC-MS verification. Supplied as a 10 mg lyophilised powder, it pairs cleanly with the rest of our research catalogue for controlled laboratory work.
